Island is pleased to share the news that MST Access analyst, Rosemary Cummins, has initiated research coverage on Island Pharmaceuticals (ASX: ILA.)

In her report, entitled, “Primed for Success”, Ms Cummins provides a summary of Island’s approach to repurposing drugs, like ISLA-101, for viral illnesses.

MST has noted a 12 month forward valuation for Island of $112m from the date of release, subject to the Company achieving its aims over this period.

To view a copy of the report, please click here.